FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3007547559> ?p ?o ?g. }

• W3007547559 endingPage "576" @default.
• W3007547559 startingPage "576" @default.
• W3007547559 abstract "<h3>Importance</h3> High blood pressure (BP) is a leading contributor to premature mortality worldwide. The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated a 27% reduction in all-cause death with intensive (vs standard) BP control. However, traditional reporting of survival benefits is not readily interpretable outside medical communities. <h3>Objective</h3> To estimate residual life span and potential survival gains with intensive compared with standard BP control in the SPRINT trial using validated nonparametric age-based methods. <h3>Design, Setting, and Participants</h3> This secondary analysis of data from an open-label randomized clinical trial included data from 102 enrolling clinical sites in the United States. Adults who were 50 years or older, were at high cardiovascular risk but without diabetes, and had a screening systolic BP between 130 and 180 mm Hg were enrolled between November 2010 and March 2013. Data analysis occurred from May 2019 to December 2019. <h3>Interventions</h3> A 1:1 randomization to intensive (target, <120 mm Hg) or standard (target, <140 mm Hg) systolic BP targets. <h3>Main Outcomes and Measures</h3> We calculated age-based estimates of projected survival (at a given age) using baseline age rather than time from randomization as the time axis. In each treatment arm at every year of age, residual life span was estimated using the area under the survival curve, up to a maximum of 95 years. Differences in areas under the survival curves reflect the estimated treatment benefits on projected survival. <h3>Results</h3> A total of 9361 adults were enrolled (mean [SD] age at randomization, 68 [9] years; 6029 [64.4%] were men; 5399 [57.7%] were non-Hispanic white individuals). Mean survival benefits with intensive vs standard BP control ranged from 6 months to up to 3 years. At age 50 years, the estimated residual survival was 37.3 years with intensive treatment and 34.4 years with standard treatment (difference, 2.9 years [95% CI, 0.9-5.0 years];<i>P</i> = .008). At age 65 years, residual survival was 24.5 years with intensive treatment and 23.3 years with standard treatment (difference, 1.1 years [95% CI, 0.1-2.1 years];<i>P</i> = .03). Absolute survival gains with intensive vs standard BP control decreased with age, but the relative benefits were consistent (4% to 9%). <h3>Conclusions and Relevance</h3> Intensive BP control improves projected survival by 6 months to 3 years among middle-aged and older adults at high cardiovascular risk but without diabetes mellitus. These post hoc actuarial analyses from SPRINT support the survival benefits of intensive BP control, especially among middle-aged adults at risk. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT01206062" @default.
• W3007547559 created "2020-03-06" @default.
• W3007547559 creator A5010456790 @default.
• W3007547559 creator A5039267010 @default.
• W3007547559 creator A5054830306 @default.
• W3007547559 creator A5061881316 @default.
• W3007547559 date "2020-05-01" @default.
• W3007547559 modified "2023-10-11" @default.
• W3007547559 title "Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span" @default.
• W3007547559 cites W2011284201 @default.
• W3007547559 cites W2092075924 @default.
• W3007547559 cites W2161557330 @default.
• W3007547559 cites W2193508485 @default.
• W3007547559 cites W2572331255 @default.
• W3007547559 cites W2749174827 @default.
• W3007547559 cites W2753244592 @default.
• W3007547559 cites W2807052238 @default.
• W3007547559 cites W2897161991 @default.
• W3007547559 cites W2902410605 @default.
• W3007547559 cites W2943969224 @default.
• W3007547559 cites W2968530115 @default.
• W3007547559 cites W2970695765 @default.
• W3007547559 cites W2990547440 @default.
• W3007547559 cites W3150595609 @default.
• W3007547559 doi "https://doi.org/10.1001/jamacardio.2019.6192" @default.
• W3007547559 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7240348" @default.
• W3007547559 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32101262" @default.
• W3007547559 hasPublicationYear "2020" @default.
• W3007547559 type Work @default.
• W3007547559 sameAs 3007547559 @default.
• W3007547559 citedByCount "24" @default.
• W3007547559 countsByYear W30075475592020 @default.
• W3007547559 countsByYear W30075475592021 @default.
• W3007547559 countsByYear W30075475592022 @default.
• W3007547559 countsByYear W30075475592023 @default.
• W3007547559 crossrefType "journal-article" @default.
• W3007547559 hasAuthorship W3007547559A5010456790 @default.
• W3007547559 hasAuthorship W3007547559A5039267010 @default.
• W3007547559 hasAuthorship W3007547559A5054830306 @default.
• W3007547559 hasAuthorship W3007547559A5061881316 @default.
• W3007547559 hasBestOaLocation W30075475591 @default.
• W3007547559 hasConcept C126322002 @default.
• W3007547559 hasConcept C168563851 @default.
• W3007547559 hasConcept C1862650 @default.
• W3007547559 hasConcept C187212893 @default.
• W3007547559 hasConcept C194828623 @default.
• W3007547559 hasConcept C204243189 @default.
• W3007547559 hasConcept C2776868573 @default.
• W3007547559 hasConcept C535046627 @default.
• W3007547559 hasConcept C71924100 @default.
• W3007547559 hasConcept C84393581 @default.
• W3007547559 hasConceptScore W3007547559C126322002 @default.
• W3007547559 hasConceptScore W3007547559C168563851 @default.
• W3007547559 hasConceptScore W3007547559C1862650 @default.
• W3007547559 hasConceptScore W3007547559C187212893 @default.
• W3007547559 hasConceptScore W3007547559C194828623 @default.
• W3007547559 hasConceptScore W3007547559C204243189 @default.
• W3007547559 hasConceptScore W3007547559C2776868573 @default.
• W3007547559 hasConceptScore W3007547559C535046627 @default.
• W3007547559 hasConceptScore W3007547559C71924100 @default.
• W3007547559 hasConceptScore W3007547559C84393581 @default.
• W3007547559 hasIssue "5" @default.
• W3007547559 hasLocation W30075475591 @default.
• W3007547559 hasLocation W30075475592 @default.
• W3007547559 hasLocation W30075475593 @default.
• W3007547559 hasOpenAccess W3007547559 @default.
• W3007547559 hasPrimaryLocation W30075475591 @default.
• W3007547559 hasRelatedWork W1932112545 @default.
• W3007547559 hasRelatedWork W2056697517 @default.
• W3007547559 hasRelatedWork W2105059445 @default.
• W3007547559 hasRelatedWork W2138201488 @default.
• W3007547559 hasRelatedWork W2155238530 @default.
• W3007547559 hasRelatedWork W2160851731 @default.
• W3007547559 hasRelatedWork W2611796762 @default.
• W3007547559 hasRelatedWork W2919555045 @default.
• W3007547559 hasRelatedWork W3159466213 @default.
• W3007547559 hasRelatedWork W4317868882 @default.
• W3007547559 hasVolume "5" @default.
• W3007547559 isParatext "false" @default.
• W3007547559 isRetracted "false" @default.
• W3007547559 magId "3007547559" @default.
• W3007547559 workType "article" @default.